Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers.
Adenocarcinoma
/ genetics
Carcinoma, Pancreatic Ductal
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Computational Biology
Gene Expression Regulation, Neoplastic
/ genetics
Glycosyltransferases
/ genetics
Humans
N-Acetylglucosaminyltransferases
/ genetics
Receptors, Notch
/ genetics
Signal Transduction
/ genetics
EOGT
LFNG
Notch
PDAC
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
07 Feb 2021
07 Feb 2021
Historique:
received:
05
01
2021
revised:
30
01
2021
accepted:
02
02
2021
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
13
4
2021
Statut:
epublish
Résumé
Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression. However, dysregulation of Notch signaling by post-translational modification of Notch receptors remains poorly understood. Here, we analyzed the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway. Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC. The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation. EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients. These results imply potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC.
Identifiants
pubmed: 33562410
pii: molecules26040882
doi: 10.3390/molecules26040882
pmc: PMC7915272
pii:
doi:
Substances chimiques
Receptors, Notch
0
Glycosyltransferases
EC 2.4.-
EOGT protein, human
EC 2.4.1.-
LFNG protein, human
EC 2.4.1.-
N-Acetylglucosaminyltransferases
EC 2.4.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP19K16073
Organisme : Japan Society for the Promotion of Science
ID : JP19KK0195
Organisme : Japan Society for the Promotion of Science
ID : JP19H03176
Organisme : Japan Society for the Promotion of Science
ID : JP19H03416
Organisme : the Foundation for Promotion of Cancer Research in Japan
ID : N/A
Organisme : the Hori Sciences and Arts Foundation
ID : N/A
Organisme : the Sasakawa Scientific Research Grant from Japan Science Society
ID : N/A
Organisme : the Takeda Science Foundation
ID : N/A
Organisme : Mitsubishi Foundation
ID : N/A
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Cancer Cell. 2003 Jun;3(6):565-76
pubmed: 12842085
Dev Cell. 2017 Jan 23;40(2):193-201
pubmed: 28089369
Pancreatology. 2018 Dec;18(8):954-961
pubmed: 30297095
Nagoya J Med Sci. 2018 Aug;80(3):299-307
pubmed: 30214079
J Biol Chem. 2008 Dec 19;283(51):35486-95
pubmed: 18948267
Cell. 2018 Feb 8;172(4):869-880.e19
pubmed: 29398116
FEBS Lett. 2018 Dec;592(23):3819-3834
pubmed: 30207383
J Mol Biomark Diagn. 2012 Apr;3(2):
pubmed: 26609466
Cancer Cell. 2014 Mar 17;25(3):318-34
pubmed: 24651013
Am J Med Genet A. 2017 Mar;173(3):790-800
pubmed: 28160419
Biochim Biophys Acta. 2009 Feb;1792(2):100-11
pubmed: 19061953
Bioinformatics. 2020 Feb 15;36(4):1143-1149
pubmed: 31503285
Glycobiology. 2015 Oct;25(10):1027-42
pubmed: 26175457
Eur J Hum Genet. 2014 Mar;22(3):374-8
pubmed: 23860037
Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Sep;44(5):699-702
pubmed: 24325093
Pharmacol Ther. 2013 Aug;139(2):95-110
pubmed: 23458608
Bioinformatics. 2015 Apr 1;31(7):1120-3
pubmed: 25414360
Bioinformatics. 2018 Nov 1;34(21):3719-3726
pubmed: 29790909
Elife. 2017 Apr 11;6:
pubmed: 28395734
Cancer Res. 2010 Jun 1;70(11):4280-6
pubmed: 20484026
J Biol Chem. 2020 Jun 19;295(25):8560-8574
pubmed: 32376684
Science. 2011 Aug 26;333(6046):1154-7
pubmed: 21798897
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Oncotarget. 2017 Jan 31;8(5):7740-7752
pubmed: 27999190
Glycobiology. 2018 May 1;28(5):295-305
pubmed: 29315387
Pancreat Disord Ther. 2013 May 30;3(114):
pubmed: 24027656
Oncogene. 2016 May 12;35(19):2485-95
pubmed: 26279302
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
J Biol Chem. 2020 Oct 23;295(43):14710-14722
pubmed: 32820046
BMC Cancer. 2014 Nov 22;14:862
pubmed: 25416148
Cell. 2009 Apr 17;137(2):216-33
pubmed: 19379690
J Surg Oncol. 2014 Oct;110(5):592-8
pubmed: 25111970
Sci Rep. 2017 Jun 23;7(1):4162
pubmed: 28646174
Development. 2008 Aug;135(16):2757-65
pubmed: 18635610
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Circ Res. 2015 Jul 3;117(2):121-8
pubmed: 25940550
Mol Cancer Ther. 2015 Jan;14(1):289-97
pubmed: 25351917
Gastroenterology. 2009 May;136(5):1741-9.e6
pubmed: 19208345
Mol Med Rep. 2018 Apr;17(4):4965-4972
pubmed: 29393429
Int J Cancer. 1975 May 15;15(5):741-7
pubmed: 1140870
J Biol Chem. 2014 Apr 18;289(16):11132-42
pubmed: 24573683
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Molecules. 2018 Jul 17;23(7):
pubmed: 30018219
FASEB J. 2020 Sep;34(9):12214-12228
pubmed: 32686876
Exp Ther Med. 2018 Jul;16(1):53-60
pubmed: 29896227
PLoS One. 2014 Nov 06;9(11):e112122
pubmed: 25375165
Onco Targets Ther. 2013 Sep 06;6:1249-59
pubmed: 24043949
J Biomol Screen. 2015 Dec;20(10):1286-93
pubmed: 26384394
Trends Mol Med. 2013 May;19(5):320-7
pubmed: 23545339
Curr Protoc Mol Biol. 2019 Sep;128(1):e100
pubmed: 31503414
Curr Opin Struct Biol. 2019 Jun;56:72-77
pubmed: 30669087